Jubilant Pharmova's USFDA inspection concludes with no observations

Jubilant Pharmova Limited announced on September 20, 2025, the completion of a Post-marketing Adverse Drug Experience (PADE) inspection by the United States Food and Drug Administration (USFDA). The inspection, which concluded on September 19, 2025, focused on Jubilant Cadista Pharmaceuticals Inc, USA, a wholly-owned subsidiary of Jubilant Pharma Limited, and closed with no observations.

The company highlighted that the zero observations reaffirm its commitment to maintaining high standards of quality, safety, and compliance. Jubilant Pharma Limited is an integrated global pharmaceutical company, operating manufacturing facilities that cater to regulated markets, including the USA and Europe.

Jubilant Pharmova Limited, globally, employs around 5,500 multicultural people and is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing, Generics, and Proprietary Novel Drugs businesses across more than 75 countries.